Combining two treatments to target uterine cancer
Combined ATR and P13k inhibition in uterine cancer
This study is looking at how two types of cancer treatments, ATR and PI3K inhibitors, can work together to help improve outcomes for people with uterine cancer, especially those with tumors that are under a lot of stress from cell replication.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11070306 on NIH RePORTER |
What this research studies
This research investigates the combined effects of ATR and PI3K inhibitors on uterine cancer, particularly focusing on tumors with high levels of replication stress. By utilizing advanced screening techniques, the study aims to identify how these two therapies can work together to improve treatment outcomes. The approach involves both laboratory experiments and potential clinical applications, targeting specific genetic alterations found in uterine cancer cells. Patients may be monitored for their response to this combination therapy, which could lead to more effective treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with uterine cancer, especially those with endometrioid or clear cell histology and specific genetic alterations.
Not a fit: Patients with uterine cancer who do not have the relevant genetic mutations or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for patients with uterine cancer, particularly those with specific genetic mutations.
How similar studies have performed: Other research has shown promising results with similar approaches, indicating potential for success in this area.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Konstantinopoulos, Panagiotis — Dana-Farber Cancer Inst
- Study coordinator: Konstantinopoulos, Panagiotis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.